RxDoctor Payments Data

Luis Navas, MD

Family Medicine · Pensacola, FLNPI 1770569238

Payments from drug & device makers

$18,147in general payments, 2019–2025

Across 1,202 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Lilly USA, LLC$2K
  • Astellas Pharma US Inc$1K
  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$17,68397%
  • Education$4633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,147 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$355,391
Medicare patients
687
Services billed
4,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$115,225
TrulicityDulaglutide45$73,924
EliquisApixaban59$71,556
OzempicSemaglutide31$49,537
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$39,063
Tresiba Flextouch U-200Insulin Degludec18$34,970
JanuviaSitagliptin Phosphate30$28,139
FarxigaDapagliflozin Propanediol26$27,049
TradjentaLinagliptin31$23,451
MounjaroTirzepatide13$19,974
MyrbetriqMirabegron17$16,078
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,492
EntrestoSacubitril/Valsartan19$14,215
XareltoRivaroxaban21$12,001
SynthroidLevothyroxine Sodium114$9,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$418$138,677137 claims
Lilly USA, LLCTrulicity, Mounjaro$1,501$93,89958 claims
PfizerEliquis$1,071$71,55659 claims
Novo NordiskOzempic$4,228$49,53731 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,088$42,54140 claims
GSKTrelegy Ellipta, Anoro Ellipta$458$41,40861 claims
MerckJanuvia$51$28,13930 claims
Astellas Pharma US IncMyrbetriq$1,474$16,07817 claims
NovartisEntresto$105$14,21519 claims
Johnson & JohnsonXarelto$678$12,00121 claims
AbbVieSynthroid$1,047$9,081114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →